| Identification | Back Directory | [Name]
ZT-12-037-01 | [CAS]
2328073-61-4 | [Synonyms]
ZT-12-037-01
2,4-Quinazolinediamine, N2-cyclopropyl-6,7-dimethoxy-N4-[1-(1-methylethyl)-4-piperidinyl]- | [Molecular Formula]
C21H31N5O2 | [MDL Number]
MFCD32197197 | [MOL File]
2328073-61-4.mol | [Molecular Weight]
385.5 |
| Chemical Properties | Back Directory | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
DMSO: 8.33 mg/mL (21.61 mM) | [form ]
Solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM[1]. | [Biological Activity]
ZT-12-037-01 is an ATP-competitive STK19 inhibitor with IC50 values of 23.96 nM and 27.94 nM for STK19 (WT) and STK19 (D89N), respectively. At a concentration of 1 μM, it is highly selective against a kinase library of 468 kinases. | [in vitro]
Treatment with ZT-12-037-01 could effectively inhibit NRAS phosphorylation. ZT-12-037-01 is an ATP-competitive inhibitor that potently inhibits melanocytic colony formation, proliferation and tumor formation driven by mutant NRAS-STK19. It's pro-apoptotic activity was significantly enhanced in cells expressing oncogenic NRAS. | [in vivo]
ZT-12-037-01 is a potent STK19 inhibitor with low toxicity in vivo. In the SK-MEL-2 xenograft model (carrying NRAS. | [target]
| Target | Value | STK19
(Cell-free assay) | 23.96 nM | STK19 (D89N)
(Cell-free assay) | 27.94 nM | < /table>[References]
[1] Yin C, et al. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. Cell. 2019 Feb 21;176(5):1113-1127.e16. DOI:10.1016/j.cell.2019.01.002 |
|
|
|
Tags:2328073-61-4
Related Product Information
|
|
187389-52-2
475110-96-4
25775-90-0
161401-82-7
|
|